Ocata preparing for Phase 2 clinical trial
Marlborough's Ocata Therapeutics has enrolled its first patient for its Phase 2 clinical trial of a treatment for dry age-related macular degeneration (dry AMD), the company announced.
The company, formerly Advanced Cell Technology, is researching treatments for eye diseases in a field known as regenerative ophthalmology. The upcoming clinical trial for dry AMD involves transplantation of its fully differentiated stem-cell line RPE — retinal pigmented epithelium — into the retina.
The purpose of the Phase 2 trial, the company said in a statement Tuesday, is to evaluate safety and explore efficacy as compared to a parallel control group. The study will include up to three cohorts of up to 20 subjects each, with some participants receiving placebos. Results from the first cohort are expected in the second quarter of 2016.
The company said its believes its RPE research has potential for developing treatments for ophthalmological conditions in addition to dry AMD, such as Stargardt’s Disease.
WBJ Web Partners
Most Recent
Most Recent
0 Comments